CYP2D6 and breast cancer: As opposed to using a surrogate marker like CYP2D6 that only explains portions of the variability in endoxifen concentrations, a more direct method for testing the hypothesis of metabolic resistance is to measure systemic levels of active metabolites and investigate their association with BC outcome.